Reference: 2019-1671 INNOWWIDE

Date: November 2019 to June 2020

Biomedal S.L was Selected from nearly 400 companies from 35 countries of the EU as one of the 50 best projects, to conduct a Viability Assessment Projects under INNOWWIDE call.

INNOWWIDE – Viability assessment of collaborative and INNOvative business solutions in WorldWIDE markets, is a Horizon 2020 project that aims to fund at least 120 European innovative SMEs and start-ups to conduct Viability Assessment Projects (VAPs) in markets outside of Europe.

Biomedal has developed an innovative technique to determine gluten immunogenic peptides (GIP) excreted in stools and urine as biomarkers to detect gluten intake (GIP Test). GIP Test is a sensitive and specific immune-technique based on ELISA and/or LFIA to detect digestive resistant peptides of gluten. It is used in a portfolio of in vitro diagnosis (IVD) and at-home kits already worldwide commercialized by Biomedal.

Nevertheless, in USA, professional healthcare and clinical laboratories are underserved due to technical and regulatory barriers. So, the overall aim of this VAP, is introducing GIP Test for professional use in the USA market.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no.822273 This document reflects only the author’s view and the Commission is not responsible for any use that may be made of the information it contains.